Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YBL-006 |
Synonyms | |
Therapy Description |
YBL-006 is a monoclonal antibody that binds to PD-1 (PDCD1) and blocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially leading to enhanced immune response and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3367). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YBL-006 | YBL006|YBL 006 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | YBL-006 is a monoclonal antibody that binds to PD-1 (PDCD1) and blocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially leading to enhanced immune response and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3367). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Unknown status | AUS | 2 |